This invention is a novel gene therapy and delivery platform to permanently restore functionality of key cells implicated in the neuro sensory path of the hearing function.
Ultimately this invention will improve and restore people’s hearing.
- Localised gene therapy delivery
- Better controlled transfection of cells
- Lower immunological reaction to the virus construct
- Long acting therapeutic effect
- Significantly improve hearing in patients already wearing hearing aids
- Gene therapy delivery platform (controller & probe)
- Gene therapy for localised tissue
- This technology also has significant applications in central nervous system disorders
UNSW is seeking a partner to license this technology and/or to work with the researchers to further develop this technology. The technology is protected by international patent application PCT/AU2016/050546.
Key Publications and Technical Data
...."The focusing of electric fields by particular cochlear implant electrode configurations led to surprisingly efficient gene delivery to adjacent mesenchymal cells. The resulting BDNF expression stimulated regeneration of spiral ganglion neurites, which had atrophied 2 weeks after ototoxic treatment, in a bilateral sensorineural deafness model. In this model, delivery of a control GFP-only vector failed to restore neuron structure, with atrophied neurons indistinguishable from unimplanted cochleae. With BDNF therapy, the regenerated spiral ganglion neurites extended close to the cochlear implant electrodes, with localized ectopic branching". Read more >
..."Here, we establish the properties of array-based electroporation affecting targeted gene delivery. The refinement of gene delivery parameters was validated in vivo in the guinea pig cochlea. These findings have significant clinical ramifications, where spatiotemporal control of gene expression can be predicted by manipulation of the electric field via current steering at a cellular level". Read more >